Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
DVAX's Cash-to-Debt is ranked higher than
96% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. DVAX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
DVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.34  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.78
DVAX's Equity-to-Asset is ranked higher than
63% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DVAX: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
DVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.28  Med: 0.75 Max: 0.93
Current: 0.78
-2.28
0.93
Piotroski F-Score: 3
Altman Z-Score: -6.97
Beneish M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2667.54
DVAX's Operating Margin % is ranked lower than
85% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. DVAX: -2667.54 )
Ranked among companies with meaningful Operating Margin % only.
DVAX' s Operating Margin % Range Over the Past 10 Years
Min: -2667.54  Med: -547.7 Max: -37.49
Current: -2667.54
-2667.54
-37.49
Net Margin % -2650.25
DVAX's Net Margin % is ranked lower than
86% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. DVAX: -2650.25 )
Ranked among companies with meaningful Net Margin % only.
DVAX' s Net Margin % Range Over the Past 10 Years
Min: -2650.25  Med: -509.28 Max: -56.15
Current: -2650.25
-2650.25
-56.15
ROE % -72.59
DVAX's ROE % is ranked lower than
72% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. DVAX: -72.59 )
Ranked among companies with meaningful ROE % only.
DVAX' s ROE % Range Over the Past 10 Years
Min: -307.22  Med: -71.52 Max: -49.94
Current: -72.59
-307.22
-49.94
ROA % -61.74
DVAX's ROA % is ranked lower than
73% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. DVAX: -61.74 )
Ranked among companies with meaningful ROA % only.
DVAX' s ROA % Range Over the Past 10 Years
Min: -85.08  Med: -52 Max: -19.74
Current: -61.74
-85.08
-19.74
ROC (Joel Greenblatt) % -759.50
DVAX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. DVAX: -759.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1231.79  Med: -852.57 Max: -172.67
Current: -759.5
-1231.79
-172.67
3-Year Revenue Growth Rate -40.00
DVAX's 3-Year Revenue Growth Rate is ranked lower than
83% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. DVAX: -40.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.1 Max: 88.2
Current: -40
0
88.2
3-Year EBITDA Growth Rate -6.40
DVAX's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. DVAX: -6.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.3  Med: -12.4 Max: 39.1
Current: -6.4
-63.3
39.1
3-Year EPS without NRI Growth Rate -7.50
DVAX's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. DVAX: -7.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.6  Med: -18.6 Max: 26.3
Current: -7.5
-60.6
26.3
GuruFocus has detected 4 Warning Signs with Dynavax Technologies Corp $DVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVAX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DVAX Guru Trades in Q1 2016

Steven Cohen 804,126 sh (New)
John Paulson 199,700 sh (+49.25%)
Chuck Royce 299,000 sh (+43.06%)
Paul Tudor Jones 36,699 sh (+26.56%)
Louis Moore Bacon Sold Out
Jim Simons Sold Out
» More
Q2 2016

DVAX Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
John Paulson 174,000 sh (-12.87%)
Steven Cohen 450,346 sh (-44.00%)
Chuck Royce 164,000 sh (-45.15%)
» More
Q3 2016

DVAX Guru Trades in Q3 2016

Paul Tudor Jones 22,654 sh (New)
Steven Cohen 1,754,000 sh (+289.48%)
John Paulson 174,000 sh (unchged)
Chuck Royce 120,000 sh (-26.83%)
» More
Q4 2016

DVAX Guru Trades in Q4 2016

Jim Simons 463,951 sh (New)
Paul Tudor Jones 63,600 sh (+180.75%)
John Paulson 174,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 111,000 sh (-7.50%)
» More
» Details

Insider Trades

Latest Guru Trades with DVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALBO, OTCPK:DGJI, OTCPK:BNOEF, NAS:ARWR, NAS:RDHL, NAS:CBMG, NAS:ABUS, OTCPK:EGRN, NAS:NYMX, OTCPK:PAIOF, NAS:CDXS, OTCPK:PHGUF, NAS:GNMX, NAS:MRTX, AMEX:PLX, NAS:NVIV, NAS:VBIV, NAS:EVGN, OTCPK:BCDA, OTCPK:SIGA » details
Traded in other countries:DYF1.Germany,
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.

Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.

Top Ranked Articles about Dynavax Technologies Corp

Steven Cohen Increases Position in Dynavax Company is one of many biopharmaceutical holdings
Steven Cohen (Trades, Portfolio) of Point72 Asset Management increased his position in Dynavax Technologies Corp. (NASDAQ:DVAX) by 375.26% on Sept. 29. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.45
DVAX's PB Ratio is ranked higher than
84% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. DVAX: 1.45 )
Ranked among companies with meaningful PB Ratio only.
DVAX' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 4.35 Max: 14.94
Current: 1.45
0.65
14.94
PS Ratio 34.32
DVAX's PS Ratio is ranked lower than
70% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. DVAX: 34.32 )
Ranked among companies with meaningful PS Ratio only.
DVAX' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 25.5 Max: 208.92
Current: 34.32
0.18
208.92
Current Ratio 3.85
DVAX's Current Ratio is ranked lower than
53% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. DVAX: 3.85 )
Ranked among companies with meaningful Current Ratio only.
DVAX' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.94 Max: 13.98
Current: 3.85
1.87
13.98
Quick Ratio 3.85
DVAX's Quick Ratio is ranked higher than
50% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. DVAX: 3.85 )
Ranked among companies with meaningful Quick Ratio only.
DVAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.94 Max: 13.98
Current: 3.85
1.87
13.98
Days Sales Outstanding 188.42
DVAX's Days Sales Outstanding is ranked lower than
89% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. DVAX: 188.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.1  Med: 57.91 Max: 188.42
Current: 188.42
8.1
188.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.10
DVAX's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. DVAX: -28.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -180.4  Med: -31.5 Max: -9.4
Current: -28.1
-180.4
-9.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.99
DVAX's Price-to-Net-Cash is ranked higher than
87% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. DVAX: 1.99 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DVAX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.85  Med: 5.2 Max: 26.38
Current: 1.99
1.85
26.38
Price-to-Net-Current-Asset-Value 1.81
DVAX's Price-to-Net-Current-Asset-Value is ranked higher than
88% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. DVAX: 1.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DVAX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.74  Med: 4.69 Max: 124
Current: 1.81
1.74
124
Price-to-Tangible-Book 1.47
DVAX's Price-to-Tangible-Book is ranked higher than
87% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. DVAX: 1.47 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DVAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.41  Med: 4.38 Max: 27.68
Current: 1.47
1.41
27.68
Price-to-Median-PS-Value 1.35
DVAX's Price-to-Median-PS-Value is ranked lower than
72% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. DVAX: 1.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.73 Max: 7.3
Current: 1.35
0.02
7.3
Earnings Yield (Greenblatt) % -252.34
DVAX's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. DVAX: -252.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -288.1  Med: 58.9 Max: 3563.3
Current: -252.34
-288.1
3563.3

More Statistics

Revenue (TTM) (Mil) $4.44
EPS (TTM) $ -3.17
Beta0.35
Short Percentage of Float24.16%
52-Week Range $3.20 - 23.62
Shares Outstanding (Mil)38.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 7 61 84
EPS ($) -3.20 -1.72 -1.21
EPS without NRI ($) -3.20 -1.72 -1.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DVAX

Headlines

Articles On GuruFocus.com
Trump Victory Gives Life to Pharma,Biotech - Take a Look at VBI Vaccines Nov 11 2016 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
VBI Vaccines: The Safer Alternative to the Struggling Dynavax Technologies Sep 06 2016 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 
Top Three Largest Insider Buys of the Past Week Nov 05 2013 
Steven Cohen, George Soros, John Paulson All Add to Holdings Mar 07 2012 
Dynavax Technologies Corp. Reports Operating Results (10-Q) Aug 02 2010 
Dynavax Technologies Corp. Reports Operating Results (10-Q) May 10 2010 
Price % Loser Stocks of The Day: SIGA Technologies Inc., Universal Travel Group, U.S. Concrete Inc., Dec 10 2009 

More From Other Websites
Dynavax to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 16 2017
Retired CEO of NBT Bancorp Inc. (NBTB) Offloads Shares, Plus Other Exciting Insider Trading Jan 27 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dynavax... Jan 13 2017
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities Jan 13 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dynavax... Jan 13 2017
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Dynavax Technologies Corporation of... Jan 13 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dynavax... Jan 13 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Jan 12 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dynavax... Jan 11 2017
DVAX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class... Jan 09 2017
Dynavax to Present at J.P. Morgan 35th Annual Healthcare Conference Jan 09 2017
DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action... Jan 07 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dynavax Technologies... Jan 06 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dynavax... Jan 06 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 06 2017
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other... Jan 05 2017
Less is Not More for Biotech Investors Jan 05 2017
Dynavax Restructures and Emphasizes Immuno-Oncology Program Jan 05 2017
Dynavax Restructures and Emphasizes Immuno-Oncology Program Jan 05 2017
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dynavax... Jan 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)